MaxCyte

Yahoo Finance • 4 days ago

MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook

Earnings Call Insights: MaxCyte (MXCT) Q4 2025 MANAGEMENT VIEW * Maher Masoud, President, CEO & Executive Director, highlighted that 2025 was a challenging year but also one of "meaningful progress for MaxCyte." The company acquired Se... Full story

Yahoo Finance • 6 days ago

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gene... Full story

Yahoo Finance • 4 months ago

MaxCyte reports Q3 results

* MaxCyte press release [https://investors.maxcyte.com/news-releases/news-release-details/maxcyte-reports-third-quarter-2025-financial-results-and] (MXCT [https://seekingalpha.com/symbol/MXCT]): Q3 net loss was $12.4 million compared to... Full story

Yahoo Finance • 4 months ago

MaxCyte outlines $17M–$19M annualized savings through restructuring while reiterating SPL revenue guidance

Earnings Call Insights: MaxCyte (MXCT) Q3 2025 MANAGEMENT VIEW * CEO Maher Masoud reported $6.8 million in total revenue for the third quarter, including $6.4 million in core revenue and $0.4 million in SPL program-related revenue, not... Full story

Yahoo Finance • 4 months ago

MaxCyte CFO to step down in first half of 2026

* MaxCyte (MXCT [https://seekingalpha.com/symbol/MXCT]) announced [https://seekingalpha.com/pr/20305110-maxcyte-announces-planned-cfo-transition-in-2026] that chief financial officer Douglas Swirsky will transition from his role in the f... Full story

Yahoo Finance • 4 months ago

MaxCyte Announces Planned CFO Transition in 2026

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gen... Full story

Yahoo Finance • 4 months ago

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gen... Full story

Yahoo Finance • 5 months ago

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November 19, 2025 ROCKVILLE, Md., Nov. 05, 20... Full story

Yahoo Finance • 6 months ago

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gen... Full story

Yahoo Finance • 6 months ago

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation c... Full story

Yahoo Finance • 6 months ago

MaxCyte announces 34% workforce reduction to cut costs

* MaxCyte (NASDAQ:MXCT [https://seekingalpha.com/symbol/MXCT]) is implementing a restructuring plan that includes a 34% reduction in its global workforce, including EOR personnel. * The move is aimed at cutting operating expenses, stre... Full story

Yahoo Finance • 6 months ago

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-ge... Full story

Yahoo Finance • 7 months ago

Brooke William buys Maxcyte (MXCT) shares worth $64,500

Director William W. Brooke purchased 50,000 shares of MAXCYTE, INC. (NASDAQ:MXCT) common stock on August 13, 2025, at a price of $1.29 per share. The total value of the purchase was $64,500. Following the transaction, Brooke directly owns... Full story

Yahoo Finance • 8 months ago

MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns

Investing.com - BTIG downgraded MaxCyte Inc. (NASDAQ:MXCT) from Buy to Neutral on Monday, citing ongoing funding challenges for the company’s cell and gene therapy customers. The stock has declined over 33% in the past week and is currentl... Full story

Yahoo Finance • 8 months ago

Which stocks are moving on Thursday?

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session. [topmovers] TOP GAINERS TICKER CHANGE COMMENT IMG [https://www.c... Full story

Yahoo Finance • 8 months ago

Traders are paying attention to the gapping stocks in Thursday's session.

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps. [gap] TOP GAP UP STOCKS TICKER CHANGE COMMENT AVAH [https://www.chartmill.com/stock/quote/A... Full story

Yahoo Finance • 8 months ago

MaxCyte signs platform license agreement with Adicet Bio

* MaxCyte (NASDAQ:MXCT [https://seekingalpha.com/symbol/MXCT]) said on Monday that it has signed a strategic platform license [https://seekingalpha.com/pr/20187448-maxcyte-signs-platform-license-agreement-with-adicet-bio] with Adicet Bio... Full story

Yahoo Finance • 8 months ago

MaxCyte Signs Platform License Agreement with Adicet Bio

MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leadin... Full story

Yahoo Finance • 8 months ago

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gen... Full story

Yahoo Finance • 9 months ago

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gen... Full story